BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
Recs
Core in my real money portfolio.
Strong cash generation and about 4% yield. Dividend doubled over the last five years and will continue to grow because they have an impressive management which is focused on shareholder value. It really impressed me that they did not give in to the money grabbing of Illumina shareholders (at least as of Jan. 2013...).
In terms of products they have a strong pipeline and don't face any kind of patent cliff like other pharma giants until at least 2015.